How to cite item

Patient-derived xenograft models to optimize kidney cancer therapies

  
@article{TAU22650,
	author = {Avi Patel and Sarah Cohen and Ravan Moret and Grace Maresh and Glenda C. Gobe and Li Li},
	title = {Patient-derived xenograft models to optimize kidney cancer therapies},
	journal = {Translational Andrology and Urology},
	volume = {0},
	number = {0},
	year = {2018},
	keywords = {},
	abstract = {Renal cell carcinoma (RCC) is the most common solid neoplasm of the adult kidney and has a high potential for developing metastatic spread. Approximately 25–30% of RCC patients have metastatic disease at presentation, and 30–40% of patients develop metastases after the initial diagnosis. Advanced renal cancer is a deadly and difficult-to-treat cancer. The 5-year survival rate of patients with metastatic disease is less than 10%, partly because RCC metastases become resistant to current therapies. Pre-clinical models may help to identify the optimum therapeutic options for individual patients. Here we reviewed various mouse xenograft methods for RCC treatment screening especially patient-derived orthotopic xenograft models. Advantages and disadvantaged of some of the models are also discussed.},
	issn = {2223-4691},	url = {http://tau.amegroups.com/article/view/22650}
}